Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Common Bile Duct Obstructed by Lipiodol After Transcater Arterial Chemoembolization for Hepatocellular Carcinoma: A Case Report

Author(s): Fulong Zhang, Jing Xu, Yuandong Zhu*, Yan Shi, Shurong Chen, Zhiwang Jin, Yuhong Jiang and Hai Wang

Volume 19, Issue 14, 2023

Published on: 06 March, 2023

Article ID: e130223213634 Pages: 7

DOI: 10.2174/1573405619666230213145111

open_access

Abstract

Background: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC), however, the complications of TACE have gradually become a concern of clinicians. Injury to the bile duct has been the focus of many scholars.

Case Presentation: HCC was diagnosed in a 51-year-old female patient, and the first TACE was performed on April 10, 2020. The second TACE was performed on October 18, 2021. After the second TACE, The patient suffered from nausea, jaundice, and body itching. Computed tomography (CT) of the abdomen showed that the lower common bile duct was obviously blocked by the solidified lipiodol accompanied by dilatation of intrahepatic and extrahepatic bile ducts on October 27, 2021. Endoscopic retrograde cholangiopancretography (ERCP) and endoscopic nasobiliary drainage (ENBD) were performed on October 29, 2021. The deposition of lipiodol in the common bile duct was significantly reduced.

Conclusion: After the transcatheter arterial chemoembolization for hepatocellular carcinoma, we should be on alert for damage to the bile duct, and pay attention to the deposition of lipiodol in the common bile duct.

Keywords: Common bile duct obstructed, lipiodol, transcater arterial chemoembolization, hepatocellular carcinoma, ENBD, computed tomography (CT).

Graphical Abstract

[1]
Watanabe Y, Ogawa M, Kaneko M, et al. Comparison of local recurrence in transcatheter arterial chemoembolization of hepatocellular carcinoma with or without accumulation of iodized oil beyond corona enhancement area: Short-term results. Radiol Oncol 2021; 56(1): 69-75.
[http://dx.doi.org/10.2478/raon-2021-0047] [PMID: 34957733]
[2]
Guo L, Wei X, Feng S, et al. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A randomized controlled trial. Hepatol Int 2022; 16(6): 1368-78.
[http://dx.doi.org/10.1007/s12072-022-10423-7] [PMID: 36271176]
[3]
Ke S, Xu Y, Lu G, et al. Therapeutic effect of hepatic artery chemoembolization combined with karelizumab in the treatment of advanced hepatocellular carcinoma. J Interven Rad 2022; 31(09): 865-70.
[4]
Xu H, Hu H, Yu X, et al. The 324th case of jaundice-intrahepatic bile duct dilatation-hepatic artery chemoembolization of biliary tract injury. Chin Med J 2014; 94(39): 3110-3.
[5]
Qiang Z, Wei R, Han W. Correlation between vascular embolization site and bile duct injury after interventional embolization of hepatocellular carcinoma. Hepatology 2020; 25(11): 1171-4.
[http://dx.doi.org/10.14000/j.cnki.issn.1008-1704.2004]
[6]
Zhang Y, Lin Z, Dong Q. Effect of hepatic artery chemoembolization after resection of primary liver cancer and its influence on serum AFP and CA19-9 levels of patients. Shandong Medicine 2018; 58(02): 52-4.
[7]
Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2016; 131(2): 461-9.
[http://dx.doi.org/10.1053/j.gastro.2006.05.021] [PMID: 16890600]
[8]
Shao Z, Liu X, Peng C, Wang L, Xu D. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: A review. World J Surg Oncol 2021; 19(1): 293.
[http://dx.doi.org/10.1186/s12957-021-02401-4] [PMID: 34598689]
[9]
Ando Y, Kawaoka T, Amioka K, et al. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma. Oncology 2021; 99(8): 507-17.
[http://dx.doi.org/10.1159/000515865] [PMID: 33946070]
[10]
Oh CH. Transcatheter arterial chemoembolization-induced bile duct necrosis with hemobilia in hepatocellular carcinoma: Endoscopic visualization and repair. Endoscopy 2021; 53(7): E265-6.
[http://dx.doi.org/10.1055/a-1260-2874] [PMID: 33003220]
[11]
Moriya T, Kawakami N, Wakai Y, Saito H, Saito K. Pulmonary lipiodol embolism following transcatheter arterial chemoembolization. Respirol Case Rep 2020; 8(9): e00678.
[http://dx.doi.org/10.1002/rcr2.678] [PMID: 33117542]
[12]
Chen S, Yu W, Zhang K, Liu W, Chen C. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatol Res 2021; 51(4): 482-9.
[http://dx.doi.org/10.1111/hepr.13620] [PMID: 33462925]
[13]
Miyayama S, Yamashiro M, Hashimoto M, et al. Blood supply of the main bile duct from the caudate artery and medial subsegmental artery of the hepatic artery: Evaluation using images obtained during transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2013; 43(11): 1175-81.
[http://dx.doi.org/10.1111/hepr.12071] [PMID: 23387506]
[14]
Xu H, Yu X, Wen X, et al. Clinical study of bile duct injury after hepatic artery chemoembolization. Chinese J General Surg 2016; 31(11): 917-20.
[15]
Kim HK, Chung YH, Song BC, et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001; 32(5): 423-7.
[http://dx.doi.org/10.1097/00004836-200105000-00013] [PMID: 11319315]

Rights & Permissions Print Cite
Article Metrics
29
2
© 2024 Bentham Science Publishers | Privacy Policy